Topo-proteomic in situ analysis of psoriatic plaque under efalizumab treatment

Skin Pharmacology and Physiology

Volumn 20, Issue 5, 2007, Pages 237-252

  Bonnekoh, B ^a   Pommer, A J ^b,c   Bockelmann R ^a,b   Hofmeister, H ^b   Philipsen, L ^c   Gollnick, H ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b SkinSysTec GmbH   (Germany)

^c MelTec GmbH and Co KG   (Germany)

Author keywords

Biologics (biologicals); CD11a; Efalizumab (Raptiva ); Multi Epitope Ligand Cartography; Proteomics; Psoriasis; Toponomics

Indexed keywords

ANTIBODY; CD2 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CD68 ANTIGEN; CD71 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN; CYTIDINE PHOSPHATE; CYTOKERATIN; DIPEPTIDYL PEPTIDASE IV; EFALIZUMAB; EPITOPE; HERMES ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; L SELECTIN; LEUKOCYTE ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MICROSOMAL AMINOPEPTIDASE; SYNDECAN 1;

AGED; ANTIGEN EXPRESSION; BINDING SITE; CELL ACTIVATION; CELL ADHESION; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; DRUG TOLERABILITY; EPIDERMIS; FEMALE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; INFLAMMATION; INFRARED SPECTROSCOPY; MALE; MICROSCOPY; PHENOTYPE; PRIORITY JOURNAL; PROTEOMICS; PSORIASIS; SKIN BIOPSY; SKIN CULTURE; STATISTICAL ANALYSIS; T LYMPHOCYTE; THICKNESS; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11A; EPITOPES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIGANDS; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MALE; MIDDLE AGED; PILOT PROJECTS; PROTEIN ARRAY ANALYSIS; PROTEOME; PROTEOMICS; PSORIASIS; ROBOTICS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34548192008     PISSN: 16605527     EISSN: None     Source Type: Journal    
DOI: 10.1159/000104422     Document Type: Conference Paper

References (37)

1. Wilsmann-Theis D, Martin S, Reber M, Kwiek B, Bieber T, Novak N: Biologicals dramatic advances in the treatment of psoriasis. Curr Pharm Des 2006;12:989-999.
2. Weller R: U.S. experience of immunomodulators in the treatment of psoriasis. Br J Dermatol 2005;152:817-818.
3. Nickoloff BJ, Stevens SR: What have we learned in dermatology from the biologic therapies? J Am Acad Dermatol 2006;54:S143-S151.
4. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 2001;357:1842-1847.
5. Mease PJ, Goffe BS, Metz J, Van der Stoep A, Finck B, Burge DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000;356:385-390.
6. Ellis CN, Krueger GG: Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-255.
7. Papp K, Bissonnette R, Krueger JG, Carvey W, Gratton D, Gulliver WP, Lui H, Lynde CW, Magee A, Minier D, Ouellet JP, Patel P, Shapiro J, Shear NH, Kramer S, Walicke P, Bauer R, Dedrick RL, Kim SS, White M, Garovoy MR: The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001;45:665-674.
8. Lebwohl M, Trying SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004-2013.
9. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Breshnahan BW, Menter A: Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290:3073-3080.
10. Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE Jr: Impact of efalizumab on psoriasis-specific patient-reported outcomes: results from three randomized placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol 2004;3:27-38.
11. Jordan JK: Efalizumab for the treatment of moderate to severe plaque psoriasis. Ann Pharmacother 2005;39:1476-1482.
12. Smith CH, Anstey AV, Barker JNWN, Burden AD, Chalmers RJG, Chandler D, Finlay AY, Griffiths CEM, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD: British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005;153:486-497.
13. Bonnekoh B, Böckelmann R, Pommer AJ, Malykh Y, Philipsen L, Gollnick H: The CD11a binding site of efalizumab in psoriatic skin tissue as analyzed by Multi-Epitope Ligand Cartography robot technology: introduction of a novel biological drug-binding biochip assay. Skin Pharmacol Physiol 2007;20:96-111.
14. Schubert W, Bonnekoh B, Pommer AJ, Philipsen L, Böckelmann R, Malykh Y, Gollnick H, Friedenberger M, Bode M, Dress AWM: Analyzing proteome topology and function by automated multi-dimensional fluorescence microscopy. Nat Biotechnol 2006;24:1270-1278.
15. Murphy RF: Putting proteins on the map. Nat Biotechnol 2006;24:1223-1224.
16. Zhou M, Veenstra TD: Multiplexed immunofluorescence microscopy for the interrogation of cellular protein complexes. Expert Rev Proteomics 2006;3:581-583.
17. Schubert W: Topological proteomics, toponomics, MELK-technology. Adv Biochem Eng Biotechnol 2003;83:189-209.
18. Bonnekoh B, Malykh Y, Böckelmann R, Bartsch S, Pommer AJ, Gollnick H: Profiling lymphocyte subpopulations in peripheral blood under efalizumab treatment of psoriasis by multi epitope ligand cartography (MELC) robot microscopy. Eur J Dermatol 2006;16:623-635.
19. Jullien D, Prinz JC, Langley RGB, Caro I, Dummer W, Joshi A, Dedrick R, Natta P: Tcell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva™): mechanisms of action. Dermatology 2004;208:297-306.
20. Perfetto SP, Chattopadhyay PK, Roederer M: Seventeen-colour flow cytometry: unraveling the immune system. Nat Rev Immunol 2004;4:648-655.
21. Franssen ME, Boezemann JB, Van de Kerkhof PC, Van Erp PE: Monitoring hyperproliferative disorders in human skin: flow cytometry of changing cytokeratin expression. Cytometry 2004;57B:32-39.
22. Goedkoop AY, de Rie MA, Teunissen MBM, Picavet DI, van der Hall PO, Bos JD, Tak PP, Kraan MC: Digital image analysis for the evaluation of the inflammatory infiltrate in psoriasis. Arch Dermatol Res 2005;297:51-59.
23. Chaurand P, Schwartz SA, Caprioli RM: Imaging mass spectrometry: a new tool to investigate the spatial organization of peptides and proteins in mammalian tissue sections. Curr Opin Chem Biol 2002;6:676-681.
24. Weinberg JM, Siegfried EC: Successful treatment of severe atopic dermatitis in a child and an adult with the T-cell modulator efalizumab. Arch Dermatol 2006;142:555-558.
25. Takiguchi R, Tofte S, Simpson B, Harper E, Blauvelt A, Hanifin J, Simpson E: Efalizumab for severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2007;56:222-227.
26. Hassan AS, Kaelin U, Braathen LR, Yawalkar N: Clinical and immunopathologic findings during treatment of recalcitrant atopic eczema with efalizumab. J Am Acad Dermatol 2007;56:217-221.
27. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M: Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002;138:591-600.
28. Krueger J, Gottlieb A, Miller B, Dedrick R, Garovoy M, Walicke P: Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque Tcells, consistent with inhibition of cutaneous T-cell trafficking (abstract). J Invest Dermatol 2000;115:333.
29. Gottlieb A, Krueger JG, Bright R, Ling M, Lebwohl M, Kang S, Feldman S, Spellman M, Wittkowski K, Ochs HD, Jardieu P, Bauer R, White M, Dedrick R, Garovoy M: Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000;42:428-435.
30. Coffey GP, Stefanich E, Palmieri S, Eckert R, Padilla-Eagar J, Fielder PJ, Pippig S: In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells. J Pharmacol Exp Ther 2004;310:896-904.
31. Coffey GP, Fox JA, Pippig S, Palmieri S, Reitz B, Gonzalez M, Bakshi A, Padilla-Eagar J, Fielder PJ: Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice. Drug Metab Dispos 2005;33:623-629.
32. Vugmeyster Y, Kikuchi T, Lowes MA, Chamian F, Kagen M, Gilleaudeau P, Lee E, Howell K, Bodary S, Dummer W, Krueger JG: Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin Immunol 2004;113:38-46.
33. Lowes MA, Chamian F, Abello MV, Fuentes-Duculan J, Lin SL, Nussbaum R, Novitskaya I, Carbonaro H, Cardinale I, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Wittkowski KM, Papp K, Garovoy M, Dummer W, Steinmann RM, Krueger JG: Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 2005;102:19057-19062.
34. Böckelmann R, Horn T, Gollnick H, Bonnekoh B: Interferon-γ- dependent in-vitro model for the putative keratin 17 autoimmune loop in psoriasis: exploration of pharmaco-and gene-therapeutic effects. Skin Pharmacol Physiol 2005;18:42-54.
35. Bonnekoh B, Böckelmann R: Keratin 17/interferon-γ autoimmune loop as a vicious circle driving psoriasis pathogenesis. J Am Acad Dermatol 2007;56:162.
36. Gaspari AA: Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 2006;54:S67-S80.
37. Glory E, Murphy RF: Automated subcellular location determination and high-throughput microscopy. Dev Cell 2007;12:7-16.